drugset / Trial / NCT00731952

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

NCT00731952

Phase 1 Completed 21 enrolled University of Virginia
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to find out what effects (both good and bad) two medications (VELCADE and Vorinostat) have on patients who have certain types of lung cancer. The study is "dose escalating" meaning that patients will receive different doses of medication depending on when they enter the study. Participation in the study will last approximately 3 months and will include an initial screening visit, a visit once each week for 3 weeks to receive the study medications, and then 2 additional visits around the time of your surgery to remove your lung cancer tumor.

Timeline

Start
2006-06
Primary completion
2012-12
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1 mg/m2
Subject Bortezomib Small molecule 1.6 mg/m2
Subject Vorinostat Small molecule 100 mg
Subject Vorinostat Small molecule 300 mg